Abstract:BRD4, a member of the bromodomain and extraterminal domain (BET) family and an important epigenetic reader, has emerged as an attractive oncology target. Cholangiocarcinoma is a lethal neoplasm without approved targeted therapies. BET bromodomain inhibitors have shown promising effects in certain cancers including cholangiocarcinoma. Recently developed BRD4 Proteolysis Targeting Chimera (PROTAC) compounds lead to fast and efficient degradation of BRD4 and provides longer-lasting effect than small molecule BRD4 inhibitors. In this study, we investigated the antitumor effect of a newly developed BRD4 degrader ARV-825 in cholangiocarcinoma. Immunohistochemistry and Western blotting were used to determine the expression level of BRD4. CCK-8 assay and BrdU ELISA assay were used to assess cell proliferation. Caspase 3/7 activity and Annexin V/PI staining were used to assess apoptosis. We demonstrated that BRD4 expression was elevated in cholangiocarcinoma tissues compared to normal bile duct or surrounding normal liver tissues. ARV-825 produced fast and long-lasting loss of BRD4 protein, resulting in more inhibition of CCA cell proliferation and induction of apoptosis than BRD4 inhibitors OTX-015 and JQ1. C-Myc is a well-known downstream target of BRD4. We found that ARV-825 suppressed c-Myc levels more effectively than BRD4 inhibitors. However, ARV-825 did not inhibit c-Myc expression in CCA cells with low basal c-Myc levels. Further analysis showed that ARV-825 significantly upregulated p21 expression and arrested cell cycle progression at G1 phase. In conclusion, BRD4 degrader ARV-825 leads to rapid and sustained degradation of BRD4 and is effective against cholangiocarcinoma.

Lethal Activity of BRD4 PROTAC Degrader QCA570 Against Bladder Cancer Cells

BRD4 Degrader ARV-825 Produces Long-Lasting Loss of BRD4 Protein and Exhibits Potent Efficacy Against Cholangiocarcinoma Cells.

Discovery of QCA570 As an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.

Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor

Identification of Highly Efficacious PROTACs Targeting BRD4 Against Acute Myeloid Leukemia: Design, Synthesis, and Biological Evaluations

BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression

Design, Synthesis, and Biological Evaluation of BRD4 Degraders.

Design, synthesis, and biological evaluation of BRD4 degrader

Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy

Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity.

Inhibition of KDM4A restricts SQLE transcription and induces oxidative stress imbalance to suppress bladder cancer

Testicular Nuclear Receptor 4 Regulates Proliferation and Apoptosis of Bladder Cancer <i>via</i> Bcl-2

Discovery of Novel Small Molecule Induced Selective Degradation of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD4 and BRD2 with Cellular Potencies.

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells.

Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors

Development of Small-Molecule BRD4 Degraders Based on Pyrrolopyridone Derivative

Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Development of Prostate Cancer-Targeting BRD4 Intramolecular Bivalent Molecular Glue Degraders